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ABSTRACT Japanese encephalitis virus (JEV) remains a leading cause of viral en-
cephalitis worldwide. Although JEV-speciﬁc antibodies have been described, an as-
sessment of their ability to neutralize multiple genotypes of JEV has been limited.
Here, we describe the development of a panel of mouse and human neutralizing
monoclonal antibodies (MAbs) that inhibit infection in cell culture of four different
JEV genotypes tested. Mechanism-of-action studies showed that many of these
MAbs inhibited infection at a postattachment step, including blockade of virus fu-
sion. Mapping studies using site-directed mutagenesis and hydrogen-deuterium ex-
change with mass spectrometry revealed that the lateral ridge on domain III of the
envelope protein was a primary recognition epitope for our panel of strongly neu-
tralizing MAbs. Therapeutic studies in mice demonstrated protection against lethality
caused by genotype I and III strains when MAbs were administered as a single dose
even 5 days after infection. This information may inform the development of vac-
cines and therapeutic antibodies as emerging strains and genotypic shifts become
more prevalent.
IMPORTANCE Although Japanese encephalitis virus (JEV) is a vaccine-preventable
cause of viral encephalitis, the inactivated and live attenuated platforms available
are derived from strains belonging to a single genotype (GIII) due to its historical
prevalence in areas of JEV epidemics. Related to this, studies with vaccines and anti-
bodies have focused on assessing the in vitro and in vivo protective responses to
homologous or heterologous GIII strains. An epidemiological shift in JEV genotype
distribution warrants the induction of broadly neutralizing antibody responses that
inhibit infection of multiple JEV genotypes. Here, we generated a panel of mouse
and human neutralizing monoclonal antibodies and evaluated their inhibitory activ-
ity, epitope location, and capacity for protection against multiple JEV genotypes in
mice.
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Despite the existence of inactivated and live attenuated vaccine platforms, Japaneseencephalitis virus (JEV) remains a primary cause of viral encephalitis. It is particu-
larly prevalent in Asia, with approximately 68,000 clinical cases (1, 2) and an estimated
10,000 to 15,000 deaths per year (1). JEV circulation is endemic in southern tropical and
subtropical areas (e.g., Australia, Indonesia, and Singapore), with epidemics occurring in
northern temperate regions (e.g., Japan, Bhutan, and Nepal) (3, 4). JEV is transmitted
primarily by the Culex tritaeniorhynchus mosquito and is maintained in an enzootic
cycle with pigs and wading birds. In contrast, humans are infected as incidental
dead-end hosts (5, 6). The high incidence of JEV in rural areas has been attributed to
the presence of open water sources, the preferred breeding grounds for Culex mos-
quitoes (7).
Approximately 5 to 15 days after mosquito inoculation of JEV, a nonspeciﬁc febrile
illness develops, characterized by malaise, headache, and general discomfort (2). Symp-
tomatic JEV infection is observed most commonly in children in areas of endemicity,
children and adults in areas with JEV epidemics, and travelers to areas of endemicity
and epidemics (3, 8). Severe clinical JEV disease occurs in about 1% of infected humans,
with progression to encephalitis, seizures, or neurological deﬁcits (9, 10). Beyond death,
which occurs in 20 to 30% of clinical cases, severe long-term complications include
paralysis, dystonia, and cognitive deﬁcits (10–12).
JEV is a ﬂavivirus of the Flaviviridae family and is related to other viruses that cause
human disease, including Zika (ZIKV), West Nile (WNV), dengue (DENV), tick-borne
encephalitis (TBEV), and yellow fever (YFV) viruses. JEV is an ~50-nm enveloped,
positive-stranded RNA virus with an ~11-kb genome ﬂanked by 5= and 3= untranslated
regions. The genome encodes a single open reading frame that is co- and posttrans-
lationally cleaved by viral and host proteases into three structural proteins (capsid [C],
premembrane [prM], and envelope [E]) and seven nonstructural proteins. The E protein
is necessary for virus binding, entry, and fusion in host cells (13) and the ectodomain
is divided into three domains: domain I (E-DI) is the central -barrel domain, domain II
(E-DII) is an extended dimerization domain with a distal hydrophobic fusion loop (FL),
and domain III (E-DIII) is an immunoglobulin-like fold (14). Structural analysis of the JEV
E protein shows a smaller dimer interface with increased contacts at the E-DI-DIII pocket
compared to those of related ﬂaviviruses (15).
Although most phylogenetic analyses deﬁne four JEV genotypes based on sequence
variation of the E protein, multiple strains belonging to a ﬁfth genotype were recently
identiﬁed in Malaysia and South Korea (16–18). The genotypes cluster within particular
geographic distributions: for example, genotype I (GI) and GIII strains are more common
in temperate regions, whereas GII and GIV strains are more common in tropical climates
(19–21). GIII has been the predominant genotype historically, and as such, existing
vaccines against JEV are derived from prototypical GIII strains such as JEV-Nakayama
and JEV-SA14 (21). Recent reports have noted a substantial increase in GI infections in
Asian countries, including China and Japan (22, 23).
The humoral response to JEV, like that of other ﬂaviviruses, is considered necessary
for limiting infection, and neutralizing antibody titers often serve as a correlate of
protection (24). Indeed, JEV type-speciﬁc mouse monoclonal antibodies (MAbs) with
protective activity (e.g., E3.3) have been identiﬁed and were derived against GIII strains
(25–28). Moreover, a humanized MAb (B2) that was derived from a chimpanzee
immunized with JE-VAX also protected mice against JEV-Nakayama, a strain of the
homologous JEV genotype (GIII) (29). Other neutralizing MAbs (e.g., 2H4 and 2F2) in
goat and monkey models of infection (30) protected against JEV strains from the
homologous genotype to which they were raised. Notwithstanding these data, no
study has comprehensively proﬁled the inhibitory activity of anti-JEV MAbs against
multiple genotypes in vitro and in vivo, and no fully human anti-JEV MAbs have been
described. The shift in prevalence from GIII to GI may require a different antibody
repertoire for protection against infection and thus has implications for the efﬁcacy of
existing vaccines that were derived from GIII strains.
Here, we generated a panel of mouse and human MAbs against JEV after immu-
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nizing mice and humans with a GIII vaccine strain (JEV-SA14-14-2) or mice with
pathogenic GII and GIII strains of JEV. Six of the mouse MAbs (JEV-31, JEV-106, JEV-128,
JEV-131, JEV-143, and JEV-169) neutralized infection of strains representative of the four
JEV genotypes (GI, GII, GIII, and GIV) that we tested to various degrees. Site-directed
mutagenesis and hydrogen-deuterium exchange mass spectrometry (HDX-MS) map-
ping data identiﬁed sites within E-DI (JEV-169), E-DIII (JEV-31, JEV-106, JEV-128, JEV-131,
JEV-143, and hJEV-69), and additional regions of the E ectodomain (JEV-117 and
hJEV-75) as key epitopes for neutralization. Passive transfer studies in lethal JEV
challenge mouse models showed protective efﬁcacy for some mouse and human MAbs
even when administered up to 5 days after GI or GIII infection. These data may be
relevant for the development of antibody-based therapeutics or anti-JEV vaccines with
broader protective activity, which may be important as the predominant genotypes
shift over time.
RESULTS
Anti-JEV MAbs. We generated a panel of neutralizing murine MAbs against JEV to
begin to address the impact of shifting genotype epidemiology on antibody-mediated
protection. We inoculated and boosted adult C57BL/6 mice deﬁcient for interferon (IFN)
regulatory factor 3 (Irf3/) with 102 focus-forming units (FFU) of a vaccine strain of JEV
(JEV-SA14-14-2). Additionally, we inoculated Irf7/ mice with JEV-Nakayama (GIII),
boosted with JEV-Bennett (GII), and administered a ﬁnal intravenous boost with JEV-
Nakayama before splenocyte-myeloma cell fusion. We immunized Irf3/ and Irf7/
rather than wild-type (WT) mice, as JEV replicated to higher titers and induced stronger
neutralizing antibody responses in these animals (data not shown). We screened ~3,800
hybridoma supernatants from ﬁve independent fusions for binding to JEV-infected cells
by ﬂow cytometry and direct virus binding by enzyme-linked immunosorbent assay
(ELISA) and cloned 13 JEV MAbs by limiting dilution for further characterization. Using
a single-endpoint neutralization assay, we identiﬁed 8 MAbs with 95% neutralizing
activity against infection of JEV-SA14-14-2 in Vero cells (data not shown).
We then tested these mouse MAbs for their ability to bind recombinant JEV E
ectodomain, JEV E-DI, JEV E-DIII, WNV E ectodomain, or ZIKV E ectodomain by ELISA
(Table 1). JEV-169 bound E-DI, and the remaining MAbs recognized E-DIII, with the
exception of JEV-117, which recognized JEV E ectodomain but not the domain frag-
ments. JEV-31 and JEV-117 showed cross-reactivity to WNV E protein, whereas JEV-143
cross-reacted with ZIKV E protein.
TABLE 1 Binding and neutralization of inhibitory anti-JEV MAbs





GIV, JKT 78872372/79 MAR 859 Nakayama SA14 SA14-14-2
Mouse
JEV-27 IgG2c DIII N 4,830 4,053 3,846 2,332 1,441 1,779 2,433
JEV-31 IgG2c DIII W 365 272 241 223 94 84 211
JEV-106 IgG2c DIII N 449 500 548 334 147 199 270
JEV-117 IgG2c N W 10,000 10,000 10,000 10,000 10,000 11 10,000
JEV-128 IgG2c DIII N 1,629 561 276 267 189 102 555
JEV-131 IgG2c DIII N 509 336 263 409 207 95 815
JEV-143 IgG2c DIII Z 435 405 358 346 368 379 818
JEV-169 IgG2c DI N 69 80 88 112 148 49 315
Human
hJEV-11 hIgG1,  DIII W 5,445 1,509 4,116 10,000 4,528 2,226 10,000
hJEV-69 hIgG1,  DIII N 1,102 335 524 2,444 475 211 3,111
hJEV-75 hIgG1,  N N 457 228 388 294 414 9 10,000
hJEV-80 hIgG1,  DIII W 3,371 1,117 1,036 10,000 857 1,007 7,733
aImmunoglobulin isotype, domain speciﬁcity, and cross-reactivity to WNV (W) and ZIKV (Z) were determined by ELISA. “N” indicates no binding to either WNV (W) or
ZIKV (Z) recombinant E protein or JEV E protein domains.
bPuriﬁed MAb was incubated with 102 FFU of the indicated JEV strain of genotypes GI to GIV for 1 h at 37°C. Fifty percent FRNT (FRNT50) values were determined by
nonlinear regression. Results are the average from three independent experiments performed in triplicate.
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To generate human MAbs against JEV, we screened neutralization proﬁles from
donors immunized with a two-dose regimen of a commercially available inactivated JEV
vaccine, IXIARO, that was based on a genotype III strain (Fig. 1A). We obtained
hybridoma supernatants derived from donors that bound to JEV-SA14-14-2, deter-
mined the single-endpoint neutralization titer (data not shown), and cloned 4 anti-JEV
MAbs. Three of the human MAbs bound to E-DIII, whereas hJEV-75 bound to the E
ectodomain but not to E-DI or E-DIII (Table 1). hJEV-11 and hJEV-80 cross-reacted with
WNV E protein, whereas hJEV-69 and hJEV-75 appeared speciﬁc to JEV and did not bind
either WNV or ZIKV E proteins.
Breadth of neutralization of MAbs. We performed focus reduction neutralization
tests (FRNTs) on Vero cells to assess the inhibitory capacity of our anti-JEV MAbs against
the vaccine strain, JEV-SA14-14-2, and available prototype strains representative of
FIG 1 Neutralization activity of anti-JEV MAbs. (A) Serum samples from humans previously immunized against JEV with an inactivated virion vaccine were
tested against a panel of JEV strains (2372/79 [GI], MAR 859 [GI], Bennett [GII], SA14 [GIII], SA14-14-2 [GIII], Nakayama [GIII], and JKT 7887 [GIV]) by focus-forming
assay (FFA) for neutralization activity. Serial serum dilutions were incubated with 102 FFU for 1 h at 37°C, and Vero cells were subsequently infected and stained.
(B) Neutralization curves of eight mouse anti-JEV MAbs (JEV-27, JEV-31, JEV-106, JEV-117, JEV-131, JEV-128, JEV-143, and JEV-169) against the indicated strains.
(C) Neutralization curves of human-derived anti-JEV MAbs (hJEV-11, hJEV-69, hJEV-75, and hJEV-80) against the indicated strains. All data are representative of
three independent experiments performed in triplicate.
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multiple genotypes. We did not test a representative genotype V strain of JEV, as one
was not available from the World Arbovirus Reference Collection. We determined the
MAb concentration that reduced the number of foci of infection by 50% (50% effective
concentration [EC50]) (Fig. 1B and C; Table 1). JEV-31 and JEV-169 had the strongest
neutralization activity against the four genotypes tested (GI, GII, GIII, and GIV), with EC50
values between 84 and 365 ng/ml and 49 and 315 ng/ml, respectively. JEV-106, JEV-128,
JEV-131, and JEV-143 had intermediate neutralizing activity, with EC50 values between
147 and 548 ng/ml, 102 and 1,629 ng/ml, 95 and 509 ng/ml, and 346 and 818 ng/ml,
respectively, against strains of the four genotypes. As expected, the JEV-SA14-14-2
vaccine and JEV-SA14 parental strain were neutralized to similar levels by most MAbs,
with the exception of JEV-117, which showed a remarkable ~1,000-fold shift in EC50
values. In general, JEV-27 and JEV-117 had the weakest neutralizing activity, with EC50
values between 1,441 and 4,830 ng/ml and 10,000 ng/ml, respectively.
We identiﬁed four human MAbs with neutralizing activity against JEV-SA14-14-2,
which we characterized in greater detail. hJEV-11 and hJEV-80 exhibited relatively weak
neutralizing activity (1,509 to 10,000 ng/ml and 857 to 10,000 ng/ml, respectively)
against the other strains tested (Fig. 1C; Table 1). In comparison, hJEV-69 and hJEV-75
inhibited infection of multiple JEV strains more potently. hJEV-69 had greater activity
against the GI strains (2372/79 and MAR 859; EC50, 335 to 1,102 ng/ml) than against the
GIV strain (JKT 7887; EC50, 3,111 ng/ml), whereas hJEV-75 had the strongest neutralizing
activity against GI, GII, and GIII strains (EC50, 9 to 457 ng/ml) but did not inhibit the GIV
strain (JKT 7887; EC50, 10,000 ng/ml). Overall, the mouse-derived MAbs had greater
breadth of neutralization against multiple genotypes of JEV than the human-derived
MAbs. This ﬁnding could reﬂect the different immunogens used (live versus inactivated
viruses for mice or humans, respectively), species-speciﬁc differences in the antibody
repertoire, or the limited size of the panel of MAbs that we obtained.
Mechanism of neutralization. Antibody neutralization of ﬂaviviruses can occur by
inhibiting attachment, internalization, and/or fusion (31). To determine how the neu-
tralizing MAbs inhibited infection in cell culture, we performed pre- and postattach-
ment neutralization assays (32–34). MAbs were incubated with JEV-SA14-14-2 before or
after virus binding to cells, and infection was measured by FRNT (32–34). As expected,
all MAbs efﬁciently neutralized infection when premixed with virus (Fig. 2A; see Fig. S1
[solid lines] in the supplemental material). All mouse MAbs also inhibited JEV infection
when added after virus adsorption to the cell surface, although to a lesser extent,
suggesting that at least part of their blocking activity was at a post-attachment step
(Fig. 2A; Fig. S1, dashed lines). Similarly, hJEV-69 and hJEV-75 neutralized in both pre-
and post-attachment assays (Fig. 2B).
We next determined whether the neutralizing mouse and human MAbs could block
fusion by adapting a virus fusion from without (FFWO) assay at the plasma membrane
(32, 33). JEV-SA14 was adsorbed to a monolayer of Vero cells on ice and subsequently
incubated with the MAbs. Fusion at the plasma membrane was induced by brief
exposure to low-pH-buffered medium at 37°C. After washing, cells were incubated
overnight in the presence of 10 nM concanamycin A1 to prevent canonical endosomal
fusion and allow viral replication. As described for other ﬂaviviruses (33), in the absence
of MAb treatment, ~20% of cells produced viral antigen that was measurable by ﬂow
cytometry; in contrast, minimal viral antigen (~2 to 3% of cells) was detected when
fusion was induced under neutral-pH conditions (Fig. 2C and D). All neutralizing mouse
MAbs tested inhibited plasma membrane fusion under acidic conditions and subse-
quent viral antigen expression. In contrast, hJEV-69 and hJEV-75 inhibited fusion at the
plasma membrane less efﬁciently (Fig. 2C and D).
Epitope mapping. To begin to assess the basis for differential inhibition by the
neutralizing MAbs, we mapped their epitopes. We deﬁned key peptide regions and
amino acid residues required for MAb binding by using both hydrogen-deuterium
exchange mass spectrometry (HDX-MS) (35) and alanine-scanning site-directed mu-
tagenesis (36) of the E protein of JEV-SA14-14-2.
Protection against JEV by Mouse and Human MAbs ®
















(i) HDX-MS. As HDX-MS should show slower exchange at MAb binding sites
(increased protection), we analyzed ﬁve mouse MAbs (JEV-31, JEV-106, JEV-128, JEV-
131, and JEV-143) that engaged E-DIII. The MAbs were mixed in a 1:1 ratio with E-DIII,
and HDX was performed for 10, 30, 60, 120, 900, 3,600, and 14,400 s. The quenching and
FIG 2 Mechanism of neutralization by anti-JEV MAbs. (A and B) The preattachment inhibition assay (solid lines) was
performed by incubating 102 FFU of JEV-SA14-14-2 with serial dilutions of MAbs starting at 10 g/ml for 1 h at 4°C
before addition to prechilled Vero cells at 4°C and subsequently following the FFA protocol. The postattachment
assay (dashed lines) was performed by adding 102 FFU of JEV-SA14-14-2 to cells for 1 h at 4°C. After extensive
washing to remove unbound virus, serial dilutions of MAbs were added, starting at 10 g/ml, and incubated for
1 h at 4°C, and the FFA then was completed at 37°C. Data are representative of three experiments performed in
triplicate. (C) The fusion-from-without (FFWO) assay was performed after incubating Vero cells at 4°C with JEV-SA14
(MOI of 50) for 2 h. For these experiments, we used JEV-SA14 instead of JEV-SA14-14-2 because it could be grown
to a higher titer. Cells were washed extensively, and the indicated MAbs were added for 30 min. Plasma membrane
fusion was induced by exposing the cells brieﬂy (~7 min) to an acidic pH buffer. After pH normalization, cells were
incubated with 10 nM concanamycin for 24 h to inhibit infection via the endosomal pathway and collected, ﬁxed,
permeabilized, and stained for E protein expression. The treatment and percentage of positive cells are shown. (D)
The data are pooled from three independent experiments, each performed in triplicate, with error bars (standard
deviation) and were analyzed using one-way ANOVA with Dunnett’s multiple comparisons to the isotype control
condition. ****, P  0.0001; ns, not signiﬁcant.
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protein digestion conditions were optimized to obtain 32 different peptides that
spanned the 11-kDa JEV E-DIII protein (Fig. S2A). All ﬁve MAbs showed changes in
deuterium uptake compared to unliganded E-DIII. Representative kinetic plots are
shown for eight of the peptides spanning E-DIII in the presence of JEV-31 (Fig. 3A). The
deuterium uptake studies showed that binding of JEV-31, JEV-106, JEV-128, JEV-131,
and JEV-143 protected regions in the N-terminal region and A strand (residues 304 to
310), BC loop (residues 326 to 342), and DE loop (residues 355 to 371) of E-DIII (Fig. 3B;
Fig. S2B), regions that correspond to the well-deﬁned lateral ridge (LR) epitope (37)
(E-DIII-LR).
FIG 3 Epitope mapping by hydrogen-deuterium exchange and alanine-scanning mutagenesis. (A) Representative HDX kinetic plots for eight different peptides
spanning JEV E-DIII in the presence (blue lines) or absence (black lines) of JEV-31. Regions showing reduced rates or extents of exchange are considered to
contain the binding epitopes. All experiments were performed in duplicate, and data are representative of two independent experiments. (B) Heat map
depicting the average difference of deuterium incorporation between E-DIII alone and the corresponding E-DIII-MAb complex states across all seven time points
(ΔD%). Negative values of ΔD% indicate less deuterium incorporation in the DIII-MAb state. The regions with signiﬁcant protection are shown in red. Peptides
with no or little change in deuterium uptake are indicated by white and green. (C) Representative alanine-scanning mutagenesis. 293T cells were transfected
with 1 g of the indicated plasmid and incubated overnight prior to ﬁxation, permeabilization, and staining with JEV-31, JEV-106, JEV-117, JEV-128, JEV-131,
and JEV-143. Loss of binding was detected by ﬂow cytometry. Data are representative of three independent experiments, with error bars (standard error of the
mean [SEM]) and were analyzed by one-way ANOVA with Holm-Sidak’s multiple comparisons of each mutant compared to V315 for each MAb. Superscript
letters indicate signiﬁcance: a, P  0.05; b, P  0.01; c, P  0.001; d, P  0.0001.
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(ii) Alanine-scanning mutagenesis. The amino acid binding sites of neutralizing
mouse and human anti-JEV MAbs also were mapped by alanine-scanning mutagenesis
and mammalian cell expression (36) of the JEV prM-E protein. Residues in the E protein
ectodomain were replaced with alanine with two exceptions: alanine residues were
mutated to serine, and cysteines were not mutated to prevent protein misfolding
(Table S1). We characterized a residue as critical for MAb binding if the mutation
resulted in less than 25% binding compared to the wild-type protein (Fig. 3C and 4). We
found that alanine substitution of certain amino acids (e.g., T321, D332, and I383),
which correspond to sites in E-DIII-LR, caused loss of binding of most of the neutralizing
murine and human MAbs tested, especially JEV-31, JEV-131, JEV-143, and hJEV-69
(Fig. 4A and B). JEV-131 showed a broader binding footprint, as loss of binding was
observed for alanine substitution of additional residues, including G299, L345, P376,
and V384. JEV-117 and hJEV-75 demonstrated loss of binding following mutations in
other regions of the E ectodomain (Fig. 4C) that correspond to previously deﬁned
epitopes for related ﬂaviviruses, including residues in the E-DI-DII-hinge region (K136
for JEV-117 and S275 for hJEV-75), E-DI-LR (L180 for hJEV-75), E-DII-hinge (E49), E-DII-LR
(N82 for hJEV-75), and E-DII-central interface (W217 for hJEV-75) (15, 38). The loss of
binding observed within E-DIII for alanine substitutions of residues F308 (JEV-117 and
hJEV-75) and F310 (JEV-117) corresponds to sites within the previously described
A-strand epitope (39) (Table S1). This pattern of mutagenesis and binding also corre-
lates with the inability of JEV-117 and hJEV-75 to recognize isolated domains by ELISA
(Table 1). JEV-169 demonstrated loss of binding with three different mutations in DI
(L25, G184, and L285) and a single mutation in DII (M204), although these residues do
not correspond to any published epitope. Because alanine substitutions can have only
moderate structural differences compared to other residues, we also made charge
substitutions in amino acids at different E-DIII epitopes, including the A strand (S309K,
K312E, and H395K), DIII-LR (S331K, S364K, N367K, and K369E), C-C= loop (T349K), and FG
loop (R387E and D389K). Loss of binding in the E-DIII-LR epitope (S331K and S364K) but
not in other E-DIII regions was observed for the murine MAbs JEV-31, JEV-106, JEV-128,
JEV-131, and JEV-143 (Table S2). Unexpectedly, we did not observe loss of binding for
hJEV-69, suggesting it may recognize E-DIII somewhat differently than the neutralizing
MAbs of mouse origin.
In vivo protection studies. To evaluate whether neutralizing MAbs could protect
against JEV infection in vivo, we developed challenge models of JEV-induced lethality
in mice by using GIII (Nakayama) and GI (MAR 859 and 2372/79) strains. Once models
were established, we treated 4- to 5-week-old male WT C57BL/6 mice on day 1 with
a single 10-g (0.5-mg/kg) prophylactic dose of seven different anti-JEV MAbs or an
isotype-control MAb and then inoculated animals on day 0 with different pathogenic
JEV strains.
(i) Nakayama (GIII). Whereas JEV-31, JEV-106, JEV-143, and JEV-169 protected all
mice from lethal infection (Fig. 5A), JEV-27, JEV-128, and JEV-131 conferred partial (25
to 89%) protection. We also observed protection (60 to 80%) with similar doses of
hJEV-69 and hJEV-75 (Fig. 5B).
(ii) MAR 859 (GI). JEV-31, JEV-128, JEV-131, and JEV-169 conferred partial protec-
tion, ranging from 40 to 55% (Fig. 5C).
(iii) 2372/79 (GI). JEV-31, JEV-131, and JEV-169 provided complete protection
against lethality, whereas JEV-106 and JEV-128 provided more limited (25 to 30%)
protection (Fig. 5D).
To deﬁne the therapeutic potential of our most protective MAbs, a single 250-g
(15-mg/kg) dose was administered to mice 5 days after infection (Fig. 5E and F).
Whereas JEV-31 and JEV-169 completely protected against lethality induced by JEV-
Nakayama (GIII), these MAbs showed more limited therapeutic activity against JEV-
2372/79 (GI), as they protected 50 to 60% of mice, respectively. Administration of
hJEV-75 at 5 days after infection also had signiﬁcant protection against both JEV-
Nakayama (GIII) and JEV-2372/79 (GI) strains. Overall, our data show that a single MAb
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that broadly neutralizes multiple JEV genotypes can provide therapeutic activity in vivo
against multiple strains.
DISCUSSION
We sought to identify murine and human MAbs that broadly neutralize infection of
JEV strains corresponding to most genotypes. We inoculated mice with attenuated or
infectious strains of JEV to generate a panel of eight anti-JEV MAbs and characterized
them at the functional and structural levels. From our analyses, we identiﬁed three
classes of antibodies based on neutralization proﬁle, epitope binding, and in vivo
FIG 4 Structural representation of JEV E epitopes deﬁned by alanine-scanning mutagenesis and HDX. (A) JEV E-DIII epitopes for each of the eight mouse and
human JEV MAbs were deﬁned by alanine-scanning mutagenesis (shaded gray boxes) and HDX (boldface letters). Genotypic differences from the JEV-SA14-14-2
strain (GIII) are highlighted by a star: V315 is A in the JEV-2372/79 (GI), JEV-MAR 859 (GI), JEV-Bennett (GII), and JEV-Nakayama (GIII) strains; S327 is T in the
JEV-2372/79 (GI), JEV-MAR 859 (GI), and JEV-Bennett (GIII) strains; K336 is N in the JEV-2372/79 (GI) and JEV-MAR 859 (GI) strains; and A366 is S in the JEV-2372/79
(GI), JEV-MAR 859 (GI), and JEV-Bennett (GIII) strains. For comparison to the JEV E-DIII epitopes, immediately below we show the structurally deﬁned E-DIII
epitopes of ZIKV in complex with ZV-2 (green, ABDE epitope), ZV-48 (cyan, C-C’) and ZV-67 (magenta, lateral ridge [LR]), WNV E16 (magenta, LR), DV1-E106
(magenta, LR), DV1-E111 (cyan, C-C= loop), DV2-1A1D-2 (pink, A strand), DV3-2H12 (light green, AB loop), and DV4-4E11 (pink, A strand). (B) JEV E-DIII epitopes
deﬁned by alanine-scanning mutagenesis are depicted on the JEV E-DIII structure (based on the full-length JEV E structure, PDB accession no. 3P54). (C) JEV
epitopes deﬁned by alanine-scanning mutagenesis, HDX mapping, and surface exposure are shown in the context of the full-length JEV E structure.
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efﬁcacy. The two MAbs JEV-27 and JEV-117 had the weakest inhibitory proﬁles. Four
MAbs (JEV-106, JEV-128, JEV-131, and JEV-143) had intermediate neutralization abilities,
and two MAbs (JEV-31 and JEV-169) were strongly and broadly neutralizing. Binding
analysis revealed two mouse MAbs (JEV-31 and JEV-117) that were cross-reactive with
WNV. JEV-143 cross-reacted with ZIKV, and ﬁve other mouse MAbs (JEV-27, JEV-106,
JEV-128, JEV-131, and JEV-169) appeared more type speciﬁc. JEV-31, which cross-
reacted with WNV and was one of the most strongly neutralizing MAbs in our panel,
recognized an epitope in the E-DIII-LR. A single JEV-speciﬁc neutralizing murine MAb,
JEV-169, mapped to E-DI. We also generated the ﬁrst human MAbs for JEV isolated from
B cells of recipients of a chemically inactivated JEV vaccine; to our knowledge, this also
is the ﬁrst isolation of human MAbs from an individual immunized with an inactivated
ﬂavivirus vaccine. We identiﬁed two strongly neutralizing JEV-speciﬁc human MAbs:
one (hJEV-69) that recognized E-DIII-LR and another (hJEV-75) that mapped to residues
in the E-DI-LR, E-DI-DII-hinge, E-DII-LR, and E-DII-hinge. Future studies will need to
assess the inhibitory potential of the anti-JEV humoral response against contemporary
strains of JEV of all genotypes, including GV strains.
Type-speciﬁc and cross-reactive neutralizing MAbs have been identiﬁed against JEV.
Although others have identiﬁed E-DIII-speciﬁc anti-JEV MAbs from mice (25, 27, 28), this
class of antibodies appears less immunodominant in humans, at least against some
(40–44) but not all (45, 46) ﬂaviviruses. Murine-derived E-DIII-speciﬁc MAbs (2H4, A3,
and E3.3) against JEV had stronger neutralizing activity in vitro than E-DII-speciﬁc MAbs
(25, 30, 47, 48). Humanization of chimpanzee-derived E-DI (A3 and B2)- and E-DIII
(E3)-speciﬁc MAbs demonstrated equivalent in vitro neutralization compared to the
FIG 5 Protective efﬁcacy of anti-JEV MAbs in mice. (A and B) Four- to 5-week-old male C57BL/6 mice were passively administered 10 g of the indicated (A)
mouse or (B) human MAb via intraperitoneal injection 1 day prior to inoculation with 102 FFU of JEV-Nakayama via the subcutaneous route. JEV-31 (n  9),
JEV-106 (n  8), JEV-143 (n  8), and JEV-169 (n  10) provided complete protection against lethality. JEV-27 (n  8), JEV-128 (n  9), and JEV-131 (n  9)
provided partial protection compared to the isotype control MAbs. (C and D) Three-week-old male C57BL/6 mice were passively administered 10 g of the
indicated MAb as described above 1 day prior to inoculation with 103 FFU of (C) JEV-MAR 859 (JEV-31, n  8; JEV-131, n  9; JEV-169, n  8) or (D) JEV-2372/79
(JEV-31, n  9; JEV-106, n  9; JEV-131, n  9; JEV-169, n  9). (E and F) Two hundred ﬁfty micrograms of the indicated MAb was administered 5 days
postinfection to (E) 4- to 5-week-old mice infected with 102 FFU of JEV-Nakayama (JEV-31, n  9; JEV-106, n  9; JEV-143, n  9; JEV-169, n  9; hJEV-75, n 
8) or (F) 3-week-old mice infected with 103 FFU of JEV-2372/79 (JEV-31, n 10; JEV-131, n 9; JEV-143, n 9; JEV-169, n 10; hJEV-75, n 9). Data are pooled
from at least two independent experiments. Survival was analyzed for each MAb compared to the isotype control MAb by the log rank test. *, P  0.05; **, P 
0.01; ***, P  0.001; ****, P  0.0001; ns, not signiﬁcant.
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parental MAbs, and this ﬁnding correlated with protection against JEV infection in mice
by the homologous genotype (GIII) (29).
We performed epitope-mapping studies on our mouse MAbs by using complemen-
tary approaches: HDX-MS and alanine-scanning mutagenesis. Epitope mapping by
HDX-MS identiﬁed a series of short peptides that were recognized by our strongest
neutralizing E-DIII-speciﬁc MAbs (JEV-31, JEV-128, JEV-131, and JEV-143). Subsequent
analysis by alanine-scanning mutagenesis conﬁrmed and extended these ﬁndings by
deﬁning individual amino acid residues in E-DIII-LR (T321, D332, and I383) required for
optimal MAb binding (JEV-31, JEV-131, JEV-143, and hJEV-69). HDX provided informa-
tion on MAb reactivity with a peptide segment but lacked residue-level speciﬁcity.
Reciprocally, alanine-scanning mutagenesis deﬁned speciﬁc amino acids required for
optimal binding but is of limited utility if mutation of more than one residue is required
for signiﬁcant loss of binding. Loss-of-binding analysis of the neutralizing hJEV-75 MAb
identiﬁed residues across E-DI and E-DII, particularly within the previously deﬁned
E-DI-LR, E-DII-LR, and E-DI-DII-hinge epitopes. JEV-117, a mouse MAb that was poorly
neutralizing, exhibited a similar loss-of-binding proﬁle to hJEV-75. Although further
studies are warranted, the differential functional activities of JEV-117 and hJEV-75 may
be due to differences in accessibility of their epitopes or afﬁnity of binding. Higher-
resolution studies, including X-ray crystallography and cryo-electron microscopy, are
necessary to determine the precise geometry of binding and a complete footprint of
interacting residues.
We observed some variation in neutralizing activity of some MAbs against different
JEV strains and genotypes. This piece of data is analogous to that observed with MAbs
against different DENV-3 genotypes (49, 50). The intergenotypic amino acid sequence
divergence in the E protein among genotypes ranges from 0.6% (GII versus GIII) to 5.6%
(GIII versus GIV) (51). Infection with one JEV genotype is believed to confer long-term
immunity against both homologous and heterologous genotypes. We assumed it
might be straightforward to generate mouse and human MAbs that neutralized all JEV
genotypes available to us. Indeed, there are limited amino acid changes in E-DIII among
the JEV strains that we tested, with only 5 amino acid differences (residues 315, 327,
333, 336, and 366); accordingly, the variation in neutralization of different JEV geno-
types by E-DIII-speciﬁc MAbs was limited (10-fold). Two MAbs (JEV-117 and hJEV-75)
effectively neutralized the JEV-SA14-14-2 vaccine strain but remarkably lost inhibitory
activity against the parental JEV-SA14 strain. These MAbs mapped to epitopes that also
contained residues outside E-DIII, in E-DI and E-DII. An alignment of the genotypic
variation in JEV sequences (Fig. S3) failed to show a direct correlation with the residues
identiﬁed in loss-of-binding studies for JEV-117 and hJEV-75. Although the sites of
genotypic variation between JEV-SA14-14-2 and JEV-SA14 are not coincident with
JEV-117 or hJEV-75 epitope residues, there are several residues in close proximity. For
JEV-117, the H/Q264 genotypic variation is within 5 Å of the epitope residue at position
262; M/K279 also is within 5 Å of epitope residue 49, and the K/E138 site of genotypic
variation is within 10 Å of epitope residue 136. For hJEV-75, the M/K279 genotypic
variation is within 5 Å of epitope residue 49 or within 10 Å of epitope residues 273 and
275. Similarly, the K/E138 site of genotypic variation is within 10 Å of epitope residue
49, and the H/Q264 site of genotypic variation is also within 10 Å of the epitope residue
262. As an alternative explanation, differences in strain and genotype residues allos-
terically could affect the display of JEV-117 and hJEV-75 epitopes. This idea has been
described as a basis for differential neutralization of ﬂavivirus genotypes by other
antibodies (52, 53). Clearly, further studies with higher-resolution epitope mapping of
the JEV-117 and hJEV-75 MAbs (e.g., atomic resolution structures of the Fab-E com-
plexes) may resolve this question of differential neutralization of JEV strains. Overall, our
results have potential implications for assessing the breadth of the protective efﬁcacy
of existing and new JEV vaccines. It may be critical to assess whether antibody
responses against the vaccine strain of a given JEV efﬁciently neutralize infection of
heterologous genotypes that may emerge.
Mechanism-of-action studies showed that all neutralizing murine E-DIII-LR MAbs
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could block virus fusion, as was observed previously for E16, a WNV-speciﬁc MAb (33).
Although hJEV-69 exhibited a loss-of-binding proﬁle similar to those of E-DIII-LR-
speciﬁc mouse MAbs, charge substitutions in this region (S331K and S364K) did not
affect hJEV-69 binding, suggesting a somewhat unique epitope. Consistent with this
observation, FFWO studies of hJEV-69 indicated that although it inhibited at a postat-
tachment stage, it did not efﬁciently block pH-dependent fusion. Although further
studies are required, the neutralizing human MAbs could block at a postentry step
before fusion. Alternatively, the FFWO, which is a measure of viral fusion at the plasma
membrane, may not fully recapitulate the events occurring in the late endosome.
We performed protection studies in vivo with our mouse and human MAbs and JEV
strains corresponding to the two most commonly circulating genotypes (GI and GIII). To
our knowledge, the protective effect of JEV MAbs against genotype I strains in vivo has
not been studied previously. Several of our neutralizing MAbs (JEV-31, JEV-106, JEV-131,
JEV143, JEV-169, and hJEV-75) completely protected against lethal JEV-Nakayama (GIII)
infection when administered as prophylaxis. A subgroup of MAbs (JEV-31, JEV-131, and
JEV-169) also completely protected against JEV-2372/79, a GI strain, with all MAbs
tested partially preventing lethal infection by a highly homologous second GI strain,
JEV-MAR 859, with 99% amino acid identity at the E protein. Remarkably, postexposure
therapeutic administration of a single dose of JEV-31 or JEV-169 at 5 days after infection
also conferred complete or partial protection against GIII or GI strains, respectively. A
single postexposure dose of hJEV-75 also provided high levels of protection against GI
or GIII strains. Although prior studies have reported in vivo efﬁcacy of murine and
humanized E-DIII MAbs against JEV (26, 29, 30), these challenge studies were performed
with single, homologous JEV genotypes, and protection was limited to prophylaxis,
with the exception of a single study (30). The postexposure protection we observed is
similar to that seen previously for other E-DIII-LR MAbs, including E16 and WNV (54) and
E106 and DENV-1 (55). One caveat of our study is that administration of anti-JEV
antibody at day 5 preceded the development of central nervous system symptoms
(e.g., seizures, tremors, paralysis, or lethargy). More detailed window-of-treatment
analysis is needed to determine which MAbs retain protective efﬁcacy after the
development of disease onset.
In summary, we identiﬁed a panel of anti-JEV MAbs that map to epitopes in E-DI and
E-DIII with broadly neutralizing activity against multiple JEV genotypes. Although both
mouse and human neutralizing MAbs can block infection at a postattachment stage,
the mouse MAbs appear to have a greater capacity to block pH-dependent viral fusion.
Studies using liposome-based fusion experiments (32, 33, 56) and cell entry assays (33)
will be required to corroborate these ﬁndings. Overall, our combination of in vitro MAb
neutralization analyses with mechanism of action, epitope mapping, and in vivo activity
provides insight into developing and reﬁning vaccine and therapeutic countermeasures
against emerging JEV strains and genotypes.
MATERIALS AND METHODS
Viruses. JEV strains 2372/79 (Thailand 1979, GenBank accession no. U70401), MAR 859 (Cambodia
1967, accession no. U70410), Bennett (Korea 1951, accession no. HQ223285), Nakayama (Japan 1935,
accession no. EF571853), SA14-14-2 (China 1954, accession no. JN604986), SA14 (China 1954, accession
no. M55506), and JKT 7887 (Indonesia 1981; accession no. L42160) were provided by the World Reference
Center for Emerging Viruses and Arboviruses (K. Plante, S. Weaver, and R. Tesh, Galveston, TX). Virus
stocks were propagated in C6/36 Aedes albopictus cells for 5 days prior to collection, and their titers were
determined by focus-forming assay (FFA) on Vero cell monolayers, as described previously (57).
MAb generation. (i) Mouse MAbs. Irf3/ mice were infected and boosted with 102 FFU of
JEV-SA14-14-2 and given a ﬁnal intravenous boost with 106 FFU of JEV-SA14-14-2 3 days prior to fusion
with P3X63.Ag.6.5.3 myeloma cells. Irf7/ mice were infected and boosted with 102 FFU of JEV-
Nakayama and JEV-Bennett, respectively, and given a ﬁnal boost with 103 FFU of JEV-Nakayama 3 days
prior to fusion. Antibodies from hybridomas that bound to JEV-infected Vero cells by ﬂow cytometry and
JEV-SA14-14-2 by direct ELISA were cloned by limiting dilution. All hybridomas were screened initially
with a single-endpoint neutralization assay using neat hybridoma supernatant incubated with 102 FFU
of JEV-SA14-14-2 for 1 h at 37°C. MAb-virus complexes were added to Vero cell monolayers for 1 h at 37°C
followed by 1% (wt/vol) methylcellulose in modiﬁed Eagle medium (MEM) supplemented with 4% fetal
bovine serum (FBS). Plates were ﬁxed with 2% paraformaldehyde (PFA) in phosphate-buffered saline
(PBS) 30 h later and sequentially stained with 500 ng/ml WNV E60 (cross-reactive MAb) (38) and
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horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG in PBS supplemented with 0.1% saponin
and 0.02% Tween 20. JEV-infected foci were visualized using TrueBlue peroxidase substrate (KPL) and
quantitated on an ImmunoSpot 5.0.37 macroanalyzer (Cellular Technologies). Hybridoma supernatants
with greater than 85% neutralization were puriﬁed commercially (Bio-X Cell) after adaptation for growth
under serum-free conditions.
(ii) Human MAbs. The human donors used in this study were born in the United States and
Colombia and had not experienced prior JEV infection. However, they were not tested for prior exposure
to other ﬂaviviruses (e.g., WNV or DENV). Donors were immunized voluntarily with a two-dose regimen
of a commercially available inactivated JEV vaccine, IXIARO, as part of an occupational exposure program.
Peripheral blood was obtained for research purposes after informed consent approximately 1 month
after boosting, with prior Institutional Review Board approval from Vanderbilt University Medical Center.
Peripheral blood mononuclear cells (PBMCs) from heparinized blood were isolated using Ficoll-
Histopaque and density gradient centrifugation. The cells were cryopreserved in the vapor phase of
liquid nitrogen until use. Ten million PBMCs were cultured in 384-well plates (Nunc) using culture
medium (ClonaCell-HY medium A; StemCell Technologies) supplemented with 8 g ml1 of the Toll-like
receptor (TLR) agonist CpG (phosphorothioate-modiﬁed oligodeoxynucleotide ZOEZOEZZZZZOEEZOEZ
ZZT; Invitrogen), 3 g ml1 of Chk2 inhibitor (Sigma), 1 g ml1 of cyclosporine (Sigma), and clariﬁed
supernatants from cultures of B95.8 cells (ATCC) containing Epstein-Barr virus. After 7 days, cells from
each 384-well culture plate were expanded into four 96-well culture plates (Falcon) using ClonaCell-HY
medium A containing 8 g ml1 of CpG, 3 g ml1 of Chk2 inhibitor, and 107 irradiated heterologous
human PBMCs (Nashville Red Cross) and cultured for an additional 4 days. Supernatants were screened
by ELISA (described below) for reactivity with JEV-SA14-14-2. Hybridoma cell lines were cloned by
single-cell ﬂow cytometric sorting in a sterile FACSAria III cytometer (BD Biosciences).
Neutralization assays. Serial dilutions of MAbs were incubated with 102 FFU of different JEV strains
for 1 h at 37°C as described previously (57). MAb-virus complexes were added to Vero cell monolayers
for 1 h at 37°C followed by 1% (wt/vol) methylcellulose in modiﬁed Eagle medium (MEM) supplemented
with 4% FBS. Plates were ﬁxed and processed as described above. Nonlinear regression analysis was
performed, and EC50 values were calculated after comparison to wells infected with JEV in the absence
of MAb.
Flavivirus E ectodomain and JEV E-DI and JEV E-DIII expression and puriﬁcation. JEV E protein
(residues 1 to 399 corresponding to the E ectodomain of the JEV-SA14-14-2 strain) was prepared as
previously described (15). A JEV E-DI synthetic gene was designed based on a DENV-4 DI construct (58)
with modiﬁcations such that JEV E residues 1 to 50 were linked to residues 135 to 195 by a glycine
dipeptide, and residues 135 to 195 were connected by a serine residue to residues 281 to 298. This
fragment was cloned into the pFM1.2 mammalian expression vector (59) downstream of a pHLsec signal
sequence and terminated with a C-terminal tobacco etch virus (TEV) protease and hexahistidine afﬁnity
tag. Transient expression and puriﬁcation were completed using established protocols (60). JEV E-DIII
(residues 299 to 399) was cloned into the NdeI and XhoI restriction enzyme sites of pET21a for expression
in BL21(DE3) Codon Plus Escherichia coli cells by autoinduction (61). The protein was refolded from
inclusion bodies and puriﬁed by size exclusion essentially as described previously (62). WNV (63) and ZIKV
(60) E ectodomain proteins were produced and puriﬁed based on established protocols.
JEV MAb domain mapping. MaxiSorp 96-well plates (Thermo, Fisher) were coated with 50 l of
4 g/ml of recombinant JEV E (15), JEV E-DI, JEV E-DIII, WNV E, or ZIKV E overnight at 4°C. Plates were
washed three times with PBS with 0.02% Tween 20 followed by incubation with PBS and 2% bovine
serum albumin (BSA) for 1 h at 37°C. MAbs were added (1 g/ml) for 1 h at room temperature. Plates
were washed again and sequentially incubated with biotin-conjugated anti-mouse IgG, streptavidin-HRP,
and 3,3=,5,5=-tetramethylbenzidine (TMB) substrate. The reaction was stopped by addition of 2 M H2SO4,
and emission (450 nm) was read using a TriStar LB 941 reader (Berthold Technologies).
Pre- and postattachment neutralization assays. For preattachment assays, serial dilutions of MAbs
were prepared at 4°C in Dulbecco’s modiﬁed Eagle medium (DMEM) with 2% FBS and preincubated with
102 FFU of JEV-SA14-14-2 for 1 h at 4°C. MAb-virus complexes were added to a monolayer of Vero cells
for 1 h at 4°C. Unbound virus was removed with three washes of chilled DMEM, and adsorbed virus was
allowed to internalize during a 37°C incubation for 1 h. Cells were overlaid with 1% (wt/vol) methylcel-
lulose in MEM supplemented with 4% FBS. For postattachment assays, 102 FFU of JEV-SA14-14-2 was
adsorbed onto a monolayer of Vero cells for 1 h at 4°C. After removal of unbound virus, serial dilutions
of MAbs were added to virus-adsorbed cells for 1 h at 4°C. Virus then was allowed to internalize for 1 h
at 37°C, and subsequently cells were overlaid with methylcellulose as described above. Thirty hours later,
the plates were ﬁxed with 2% PFA and analyzed for antigen-speciﬁc foci as described above.
Fusion blockade assay. The assay for plasma membrane fusion inhibition with ﬂavivirus MAbs was
described previously (32–34). Brieﬂy, Vero cells (2  104 per well) were seeded in ﬂat-bottom 96-well
plates overnight at 37°C. The following day, cells were preincubated with 10 nM concanamycin A (Sigma
catalog no. C9705), which blocks acidiﬁcation of endosomes and viral fusion, for 30 min on ice and
subsequently incubated with JEV-SA14 (multiplicity of infection [MOI] of 50) for 2 h. Cells were washed
twice with chilled PBS followed by incubation with 100 g/ml (murine) or 50 g/ml (human) MAbs for
30 min on ice. Cells were pH shifted with warmed DMEM (buffered to pH 5.5 or control pH 7.5) at 37°C
for ~7 min. The cells were rinsed and incubated for 24 h at 37°C in DMEM with 10 nM concanamycin A.
Subsequently, cells were rinsed, ﬁxed, permeabilized, and sequentially stained for 1 h at 4°C with JEV-13
(1 g/ml) and goat anti-mouse Alexa Fluor 647-conjugated secondary antibody (1:2,000). Samples were
processed by ﬂow cytometry (MacsQuant), and data were analyzed using FlowJo software.
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Hydrogen-deuterium exchange. Continuous HDX labeling of JEV E-DIII with or without the MAbs
was performed at 25°C for 0, 10, 30, 60, 120, 900, 3,600, and 14,400 s as previously described with the
following modiﬁcations (64). Brieﬂy, stock solutions of JEV E-DIII both with and without the MAbs were
prepared in PBS (pH 7.4) and incubated at 25°C for at least 1 h. Continuous labeling with deuterium was
initiated by diluting the stock samples 10-fold in deuterated PBS buffer (Sigma-Aldrich). HDX control
samples (nondeuterated) were prepared in the same way with H2O. Quenching was performed under
reducing conditions by adding a solution of 500 mM Tris (2-carboxyethyl)phosphine hydrochloride (TCEP
HCl) and 4 M guanidine hydrochloride in PBS buffer (pH 7.4 [adjusted using sodium hydroxide]) to the
reaction vial at a 1:1 vol/vol ratio. The sample was mixed and incubated for a minute at 25°C before being
loaded onto our custom-built HDX platform for desalting, online pepsin digestion, and reversed-phase
separation and directly injected into the mass spectrometer for analysis.
The sample was passed over a custom-packed 2- by 20-mm pepsin column at 200 l/min; immo-
bilized pepsin was prepared according to a published protocol (65). The peptides resulting from
digestion were captured by a 2.1- by 20-mm Zorbax Eclipse XDB-C8 trap column (Agilent) and desalted
at 200 l min1 of H2O containing 0.1% triﬂuoroacetic acid for 3 min. The peptides were separated by
a 2.1  50 mm C18 column (2.5-m XSelect CSH C18; Waters) with a 9.5-min gradient of 5 to 100%
acetonitrile in 0.1% formic acid at a ﬂow rate of 100 l min1 delivered by a LEAP 3 Ti pump (Leap
Technologies, NC). The linear part of the gradient from 0.3 min to 5.5 min raised the acetonitrile content
from 15% to 50%, during which time most of the peptides eluted from the C18 column. The entire ﬂuidic
system was kept in an ice bath, except for the pepsin column, to minimize back exchange. Duplicate
measurements were carried out for each of the time points.
HDX data analysis and epitope assignment. Acquired spectra were analyzed using HDX work-
bench software (66) against a peptide set generated as described below. The deuterium level was
normalized to the maximum deuterium concentration (80%) contained in the reaction vial. The peptide
list used to search the HDX data was identiﬁed ﬁrst by a tandem-MS experiment in a data-dependent
mode on a linear trap quadrupole-Fourier transform (LTQ-FT) mass spectrometer (Thermo). The six most
abundant ions were submitted to collision-induced dissociation fragmentation. Product-ion spectra were
then submitted to MassMatrix (version 2.4.2) for identiﬁcation (67) and manually inspected, and the
validated peptides were used for the HDX analysis. The epitopes were identiﬁed as regions/sequences of
amino acids (not single residues) that show a signiﬁcant difference in HDX for the bound versus unbound
states, as determined from the peptide-level HDX-MS data. Criteria for the selection of peptides as
potential epitopes are explained further in the Immune Epitope Database (IEDB) submission mentioned
below in the “Accession number(s)” section.
Site-directed mutagenesis epitope mapping. Epitope mapping was performed by alanine-
scanning mutagenesis as described previously (36). A JEV prM-E protein expression construct (based on
JEV-SA14-14-2) was subjected to commercial alanine-scanning mutagenesis (Genewiz) to generate a
mutant library. Each residue within the JEV E protein was changed to alanine, with alanine codons
mutated to serine and cysteine residues left unchanged. In total, 400 mutants were generated and
sequence conﬁrmed. Each JEV E protein mutant was transfected into human 293T cells and allowed to
express for 24 h and then ﬁxed and permeabilized with Foxp3 transcription factor staining buffer
(Thermo catalog no. 00-5523-00). Cells were incubated sequentially with puriﬁed MAbs at concentrations
optimized for staining (range, 30 to 1,000 ng/ml) and Alexa Fluor 647-conjugated secondary antibody
(Invitrogen) in permeabilization buffer. Fluorescence signal was detected by ﬂow cytometry (MacsQuant)
and analyzed using FlowJo software. Antibody reactivity against each mutant was compared to that of
the WT prM-E protein after subtracting the signal from mock-transfected controls and normalizing to the
signal from WT prM-E transfected controls. Mutations were identiﬁed as critical to the MAb epitope if the
mutants showed less than 25% binding compared to the wild type. For charge mutants, we substituted
residues in the A strand (S309K, K312E, and H395K), DIII-LR (S331K, S364K, N367K, and K369E), C-C= loop
(T349K), and FG loop (R387E and D389K) and transfected and stained as described above.
Mouse experiments. Animal studies were carried in accordance with the recommendations of the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and were approved
by the Institutional Animal Care and Use Committee at the Washington University School of Medicine
(assurance no. A3381-01). Mice were inoculated with JEV after induction of anesthesia using ketamine
hydrochloride and xylazine, and all efforts were made to minimize pain and suffering. Antibody
protection studies were performed according to the models described below.
(i) Genotype I. WT C57BL/6 male mice (3 weeks old; Jackson Laboratories) were inoculated with 103
FFU of JEV-MAR 859 or JEV-2372/79 subcutaneously in the footpad. Anti-JEV or isotype control (CHK-152)
MAbs were administered intraperitoneally as a single dose on day 1 (10 g, 0.5 mg/kg) or day 5
(250 g, 12.5 mg/kg) after infection. Animals were monitored for lethality for 28 days.
(ii) Genotype III. WT C57BL/6 male mice (4 to 5 weeks old; Jackson Laboratories) were inoculated
with 102 FFU of JEV-Nakayama subcutaneously in the footpad. Anti-JEV or isotype control (CHK-152)
MAbs were administered intraperitoneally as a single dose on day 1 (10 g, 0.5 mg/kg) or day 5
(250 g, 12.5 mg/kg) after infection. Animals were monitored for lethality for 28 days.
Statistical analysis. Statistical signiﬁcance of FFWO was determined by one-way ANOVA with
Dunnett’s multiple comparisons to an isotype control MAb. Statistical signiﬁcance of alanine shotgun
mutagenesis was determined by one-way ANOVA with Holm-Sidak’s multiple comparisons of each
mutant to V315 for each MAb. Kaplan-Meier survival curves were analyzed by the log rank test for each
MAb compared to an isotype control MAb.
Accession number(s). The epitopes of the ﬁve JEV-speciﬁc MAbs (E31, E106, E128, E131, and E143)
have been deposited in the Immune Epitope Database (IEDB) under submission no. 1000721.
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